Three stocks to buy, as recommended by Ankush Bajaj: Axis Bank: Buy at ₹1,045 | Target ₹1,134-1,140 | Stop loss ₹ 998 On the hourly chart, the Axis Bank stock has given a triangle breakout. Additionally, it forms a head and shoulders pattern. The ADX is at 35, indicating strong momentum. JSW Energy: Buy at
VANCOUVER, BC, Aug. 22, 2024 /PRNewswire/ – Wheaton Precious Metals™ Corp. (“Wheaton” or the “Company”) is pleased to announce that it will host an Investor Day webcast on Tuesday, September 24, 2024, starting at 9:00am Eastern Time. Speakers will include Randy Smallwood, President and Chief Executive Officer, as well as the Wheaton Executive team. In
A-Mark Precious Metals (NASDAQ: AMRK) has scheduled its fiscal fourth quarter and full year 2024 earnings call for Thursday, August 29, at 4:30 p.m. ET. The company, a leading integrated precious metals platform, will release its financial results for the period ended June 30, 2024, prior to the call. Management
2:34 PM Marksans Pharma hits 52-week high after USFDA issues EIR for Goa facility Shares of Marksans Pharma soared up to 1.98 per cent at Rs 220.14 per share on the BSE in Tuesday’s intraday trade. This came after the pharmaceutical company on Tuesday said that it has received an establishment inspection report (EIR) from
Jaguar Health (NASDAQ:JAGX) announced that Hong Kong’s Intellectual Property Department has issued a new patent to Napo Pharmaceuticals, a Jaguar family company, for methods of treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal using crofelemer. This patent strengthens Jaguar’s IP
8:52 AM ‘Nifty is poised for a potential uptick as bulls look to capitalise on positive momentum from Wall Street’ — Nifty is poised for a potential uptick as bulls look to capitalise on positive momentum from Wall Street –Traders are likely to adopt a risk-on approach, driven by strong cues
Andean Precious Metals Corp. (TSXV: APM) (OTCQX: ANPMF) held its Annual General Meeting of Shareholders on August 15, 2024. The meeting saw a strong shareholder turnout, with 88.37% of the company’s total issued and outstanding shares represented. Shareholders approved all management resolutions, including: Fixing the number of directors at seven
TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications
EDINBURGH, Scotland, Aug. 28, 2024 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has received a patent grant from European Patent Office (EPO) covering the use of modified gamma delta